Clinical Trial VICCTHN1318

Title

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Principal Investigator(s)

Leon Parks

Details

  • Protocol No. VICCTHN1318
  • Open Date: 09/19/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: To compare the efficacy of selumetinib with radioactive iodine therapy (RAI), versus placebo with RAI, by assessment of complete remission rate at 18 months post RAI treatment in the overall study population. To compare the efficacy of selumetinib with RAI, versus placebo with RAI, by assessment of complete remission rate at 18 months post RAI treatment in a subgroupof patients with tumours known to be mutation positive for BRAF or NRAS.
  • Disease Sites: Thyroid
  • Therapies: Hormonal Therapy; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: Selumetinib; Thyrogen
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01843062
  • Secondary Protocol No: D1532C00065

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.